Is Werewolf Therapeutics, Inc. (HOWL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 120.9% / 30% | 361.9% / 30% | 0.0% / 30% | 354.01% / 5% | ✗ NOT HALAL |
| DJIM | 120.9% / 33% | 361.9% / 33% | 0.0% / 33% | 354.01% / 5% | ✗ NOT HALAL |
| MSCI | 29.2% / 33% | 87.4% / 33% | 0.0% / 33% | 354.01% / 5% | ✗ NOT HALAL |
| S&P | 120.9% / 33% | 361.9% / 33% | 0.0% / 33% | 354.01% / 5% | ✗ NOT HALAL |
| FTSE | 29.2% / 33% | 87.4% / 33% | 0.0% / 50% | 354.01% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -123.9% | |
| Return on Assets (ROA) | -38.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$56M |
| Free Cash Flow | -$56M |
| Total Debt | $37M |
| Debt-to-Equity | 38.0 |
| Current Ratio | 1.6 |
| Total Assets | $127M |
Price & Trading
| Last Close | $0.86 |
| 50-Day MA | $0.69 |
| 200-Day MA | $1.11 |
| Avg Volume | 488K |
|
52-Week Range
$0.53
| |
About Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Werewolf Therapeutics, Inc. (HOWL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Werewolf Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Werewolf Therapeutics, Inc.'s debt ratio?
Werewolf Therapeutics, Inc.'s debt ratio is 120.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 29.2%.
What are Werewolf Therapeutics, Inc.'s key financial metrics?
Werewolf Therapeutics, Inc. has a market capitalization of $38M, and revenue of $2M. Return on equity stands at -123.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.